Skip to main content
Resources are available to help inform next steps for your patients with elevated Lp(a).

ASCVD, atherosclerotic cardiovascular disease; CPT, current procedural terminology; CV, cardiovascular; ICD-10, international classification of diseases, tenth revision; Lp(a), Lipoprotein (a).


References: 1. Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024;18(3):e308-e319. 2. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153:e1-e123. Published online March 13, 2026. doi:10.1161/CIR.0000000000001423 3. Jawi MM, Frohlich J, Chan SY. Lipoprotein(a) the insurgent: a new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule. J Lipids. 2020;2020:3491764. 4. Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692-711. 5. Reyes-Soffer G, Ginsburg H, Berglund L, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(1):e48-e60. 6. Wilson DP, Jacobson TA, Jones PH, et al. Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13(3):374-392. 7. Rallidis LS, Pavlakis G, Foscolou A, et al. High levels of lipoprotein (a) and premature acute coronary syndrome. Atherosclerosis. 2018;269:29-34. 8. Tian X, Zhang N, Tse G, et al. Association between lipoprotein(a) and premature atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Eur Heart J. 2024;4(3):oeae031. 9. Farzam K, Senthilkumaran S. Lipoprotein a. In: StatPearls. StatPearls Publishing; 2022. 10. Engler RJM, Brede E, Villines T, et al. Lipoprotein(a) elevation: a new diagnostic code with relevance to service members and veterans. Fed Pract. 2019;36(suppl 7):S19-S31. 11. Quest Diagnostics. Lipoprotein (a). Accessed June 12, 2025. https://testdirectory.questdiagnostics.com/test/test-guides/TS_Lipoprotein/lipoproteina 12. Kohn B, Ashraf AP, Wilson DP. Should lipoprotein(a) be measured in youth? J Pediatr. 2021;228:285-289. 13. Willeit P, Kiechl S, Kronenberg F, Mora S, Stroes ESG, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a). J Am Coll Cardiol. 2014;64(9):851-860. 14. Madsen CM, Kamstrup PR, Langsted A, et al. Lipoprotein(a)-lowering by 50 mg/dL (105 nmol/L) may be needed to reduce cardiovascular disease 20% in secondary prevention. Arterioscler Thromb Vasc Biol. 2020;40:255-266. 15. Willeit P, Ridker P, Nestel P, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018;392(10155):1311-1320. 16. Clarke R, Peden J, Hopewell J, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518-2528.